Quinine improves results of intensive chemotherapy (1C) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP): Updated results of a randomized study

Advances in Experimental Medicine and Biology

Volumn 457, Issue , 1999, Pages 35-46

  Wattel, E ^a   Solary, E ^a   Hecquet, B ^a   Caillot, D ^a   Ifrah, N ^a   Brion, A ^a   Milpied, N ^a   Janvier, M ^a   Guerci, A ^a   Rochant, H ^a   Cordonnier, C ^a   Dreyfus, F ^a   Veil, A ^a   Hoang Ngoc, L ^a   Stoppa, A M ^a   Gratecos, N ^a   Sadoun, A ^a   Tilly, H ^a   Brice, P ^a   Lioure, B ^a   Desablens, B ^a   Pignon, B ^a   Abgrall, J P ^a   Leporrier, M ^a   Dupriez, B ^a   Guyotat, D ^a   Lepelley, P ^a   Fenaux, P ^a,b   more..

^a Groupe GOELAMS   (France)

^b CHU Rouen BG   (France)

Author keywords

Drug resistance; Intensive chemotherapy; Mdr; Myelodysplastic syndromes; Quinine

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; GLYCOPROTEIN P; MITOXANTRONE; QUININE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE; GENETICS; HUMAN; KARYOTYPING; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REMISSION; SURVIVAL;

ADULT; AGED; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CYTARABINE; DISEASE PROGRESSION; FEMALE; GENES, MDR; HUMANS; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; MYELODYSPLASTIC SYNDROMES; P-GLYCOPROTEIN; PHENOTYPE; QUININE; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 0032619948     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4811-9_5     Document Type: Article

References (37)

1. Martial P., Ferrant A., Michaux J.L., Sokal G. (1988) ; Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome. Hemalol Oncol, 6 : 299-305.
2. Michels SD., Me Kenna RW., Arthur DC., Brunning RD. (1985) Therapy related acute myeloid leukemia and myelodysplastic syndrome : a clinical and morphologic study of 65 cases. Blood, 65 : 1364-1372.
3. Hoyle CF., De Bastos M., Wheatley K., Sherrington P.D., Fischer P.J., Rees J.K.H., Gray R., Hayhoe F.G.J. (1989) AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. Br J Haematol, 72 : 45-53.
4. De Witte T., Muus P., De Pauw B., Haanen C. (1990) Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer, 66, 831-837.
5. Fenaux P., Morel P., Rose C., Lai J.L., Jouet J.P., Bauters F. (1991). Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol, 77, 497-501.
6. De Witte T., Suciu S., Peetermans M., Fenaux P., Strijckmans P., Hayat M., Jaksic J., Selleslag D., Zittoun R., Dardenne M., Solbu G., Zwierzina H., Muus P. (1995) A pilot study of intensive chemotherapy for bad prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia, 9, 1805-1811.
7. Berstein S., Brunetto V., Davey F., Mayer RJ., Wurster-Hill D., Schiffer C., Bloomfield C. (1993) Intensive chemotherapy for patients with myelodysplastic syndromes. Blood, 82, (suppl 1), 1960.
8. Ruutu T., Hänninen A., Järventie G., Koistinen P., Koivunen E., Kätkä K., Nousiainen T., Pelliniemi T.T., Remes K., Timonen T., Volin L., Elonen E. (1994) Intensive treatment of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia subsequent to MDS with idarubicin and cytarabine (abstract). Br J Haematol, 87 (suppl. 1) : 19.
9. Aul C., Runde V., Germing U., Burk M., Heyll A., Hildebrandt B., Willers R. (1995) Remission rates, survival and prognostic factors in 94 patients with advanced MDS treated with intensive chemotherapy. Ann Hematol. 70 (suppl 2), A138.
10. Aul C., Runde V., Gattermann N., Germing U., Schneider W., (1994) Treatment of advanced primary myelodysplastic syndromes with AML-type chemotherapy: results in 76 patients. Leuk Res, 18, suppl : 22 (abstr).
11. Hiddemann W., Büchner T., Wörmann B., Koch P., Aul C., Balleisen L., Bennet J. (1995) Intensive therapy of high risk myelodysplastic syndromes with sequential intermediate dose cytosine arabinoside and mitoxantrone with or without GM-CSF (abstract). Ann Hematol, 70 (suppl II) : A109.
12. Gore S.D., Burke P.J. (1995) Long-term survival of subsets of patients with advanced myelodysplastic syndromes (MDS) treated with intensive chemotherapy (abstract). Blood, 86 (suppl 1) : 339a.
13. Wattel E., de Botton S., Laï J.L., Preudhomme C, Lepelley P., Bauters F., Penaux P. (1997). Long term follow up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long survivors and outcome of partial responders. Br J Haematol, 98, 983-991.
14. Gardin C., Chaibi P., de Revel T., Rousselot P., Turlure P., Micléa J.M., Nédellec G., Dombret H. (1997) Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogcnous leukemia. Leukemia, 11 : 16-21.
15. Lepelley P., Soenen V., Preudhomme C., Lai J.L., Cosson A., Fenaux P. (1994). Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia, 8, 998-1004.
16. Bennis S., Ichas F., Robert J. (1995). Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line. Int J Cancer, 62, 283-90.
17. Dorr R.T., Liddil J.D. (1991). Modulation of mitomycin C-induced multidrug resistance in vitro. Cancer Chemother Pharmacol, 27, 290-4.
18. Genne P., Duchamp O., Solary E., Pinard D., Belon J.P., Dimanche-Boitrel M.T., Chauffert B. (1994). Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM. Leukemia, 8, 160-4.
19. Malayeri R., Filipits M., Suchomel R.W., Z'chbauer S., Lechner K., Pirker R. (1996). Multidrug resistance in leukemias and its reversal. Lenk Lymphoma, 23, 451-8.
20. Solary E., Velay I., Chauffert B., Caillot D., Bidan J.M., Dumas M., Casasnovas O., Guy H. (1990). Quinine circumvents the doxorubicin resistance of a multidrug resistant human leukemic cell-line, K562/DXR. Nouv Rev Fr Hematol, 32, 361-3.
21. Sonneveld P. (1996). Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. Eur J Cancer, 6, 1062-1069.
22. Wigler P.W., Patterson F.K. (1994). Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochim Biophys Acta, 1189, 1-6.
23. Pajeva I.K., Wiese M., Cordes H.P., Seydel J.K. (1996). Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability. J Cancer Res Clin Oncol, 122, 27-40.
24. Solary E., Bidan J.M., Calvo F., Chauffert B., Caillot D., Mugneret F., Gauville C., Tsuruo T., Carli P.M., Guy H. (199 la). P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma. Leukemia, 5, 592-7.
25. Solary E., Velay I., Chauffert B., Bidan J.M., Caillot D., Dumas M., Guy H. (I991b). Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ ADM. Cancer, 68, 1714-9.
26. Solary E., Caillot D., Chauffert B., Casasnovas R.O., Dumas M., Maynadie M., Guy H. (1992). Feasibility of using quinine, a potential multidrug resistance- reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol, 10, 1730-6.
27. Solary E., Witz B., Caillot D., Moreau P., Desablens B., Cahn J.Y., Sadoun A., Pignon B., Berthou C., Maloisel F., Guyotat D., Casassus, P, Ifrah N., Lamy Y., Audhuy B., Colombat P., Harousseau J.L. (1996). Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood, 88, 1198-1205.
28. Leith C.P., Chen I.M., Kopecky K.J., Appelbaum F.R., Head D.R., Godwin J.E., Weick J.K., Willman C.L. (1995). Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+and MDR1+/efflux- cases. Blood, 86, 2329-2342.
29. Morel P., Hebbar M., Lai J.L., Duhamel A., Preudhomme C., Wattel E., Bauters F., Fenaux P. (1993). Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia, 7, 1315-23.
30. Kuwazuru Y., Yoshimura A., Hanada S., Utsunomiya A., Makino T., Ishibashi K., Kodama M., Iwahashi M., Arima T., Akiyama S. (1990). Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer, 66, 868-73.
31. Wood P., Burgess R., MacGregor A., Yin J.A. (1994). P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol, 87, 509-14.
32. Sato H., Preisler H., Day R., Raza A., Larson R., Browman G., Goldberg J., Vogler R., Grunwald H., Gottlieb A., et al. (1990). MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol, 75, 340-5.
33. Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. (I992). Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood, 79, 473-476.
34. Marie J.P., Legrand O., Russo D., Zhou D., Suberville A.M., Zittoun R. (1992). Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: sequential analysis. Leak Lymphoma, 8, 261-265.
35. Hegewisch-Becker S., Hossfeld D.K. (1996). The MDR phenotype in hematologie malignancies: prognostic relevance and future perspectives. Ann Hematol, 72, 105-117.
36. Guerci A., Merlin J.L., Missoum N., Feldmann L., Marchai S., Witz F., Rose C, Guerci O. (1995). Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood, 85, 2147-2153.
37. Pirker R., Wallner J., Geissler K., Linkesch W, Haas O.A., Bettelheim P., Hopfner M., Scherrer R., Valent P., Havelec L., et al. (1991). MDR1 gene expression and treatment outcome in acute myeloid leukemia [see comments]. J Natl Cancer Inst, 83, 708-712.